PAI-1
- CAS No.
- 31514-41-7
- Chemical Name:
- PAI-1
- Synonyms
- PAI-1;ARMAPE;PAI-1, RAT;MOUSE PAI-1;PAI-1, MOUSE;PAI-1, HUMAN;PAI-1, MUTANT, MOUSE;PLASMINOGEN ACTIVATOR INHIBITOR 1;PLASMINOGEN ACTIVATOR INHIBITOR-1, RAT;MOUSE PLASMINOGEN ACTIVATOR INHIBITOR-1
- CBNumber:
- CB1438644
- Molecular Formula:
- C27H47N9O9S
- Molecular Weight:
- 673.78
- MDL Number:
- MFCD00080197
- MOL File:
- Mol file
PAI-1 price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Sigma-Aldrich | 528205 | Plasminogen Activator Inhibitor-1, Human, Recombinant The Plasminogen Activator Inhibitor-1, Human, Recombinant controls the biological activity of Plasminogen Activator. This small molecule/inhibitor is primarily used for Protease Inhibitors applicatio | 50μg | $430 | 2026-04-30 | Buy | |
| Usbiological | 549321 | Plasminogen Activator Inhibitor 1 PurifiedbyProteinA/Gaffinitychromatography. | 200ul | $694 | 2026-06-03 | Buy | |
| Usbiological | 549320 | Plasminogen Activator Inhibitor 1 PurifiedbyProteinA/Gaffinitychromatography. | 200ul | $694 | 2026-06-03 | Buy | |
| Usbiological | 549319 | Plasminogen Activator Inhibitor 1 PurifiedbyProteinGaffinitychromatography. | 200ul | $518 | 2026-06-03 | Buy | |
| Usbiological | 549318 | Plasminogen Activator Inhibitor 1 PurifiedbyProteinA/Gaffinitychromatography. | 200ul | $545 | 2026-06-03 | Buy |
PAI-1 Chemical Properties, Uses, Production
Biological Activity
Cell permeable: no', 'Primary Target
Tissue plasminogen activator (tPA) and urokinase (uPA)', 'Product does not compete with ATP.', 'Reversible: no
Enzyme inhibitor
This 402-residue serine protease inhibitor, or serpin (MW = 45074 g/mol; Abbreviation: PAI-1) binds to and inhibits plasminogen activators-tissuetype plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA). This inhibition reduces plasmin production and suppresses dissolution of fibrin clots. Elevated PAI-1 levels correlate with an increased cardiovascular disease risk, a behavior that has also been linked to obesity and metabolic syndrome. Pharmacological suppression of PAI-1 is a likely way to prevent or treat vascular disease. Reduced PAI-1 levels may result in increased fibrinolysis and an associated bleeding diathesis. PAI-1 was initially identified in the 1980s, and the first reported case of PAI-1 deficiency appeared in 1989. Unambiguous proof that PAI-1 deficiency as a cause of a bleeding disorder has been rare, but use of selective PAI inhibitors (See PAI-749) may clarify this point. Because of lack of standardized commercially available PAI-1 activity assay sensitive in the lowest range, the true prevalence of this rare condition has yet to be established.
PAI-1 Preparation Products And Raw materials
Raw materials
Preparation Products
PAI-1 Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Shanghai Yaji Biological Technology Co., Ltd. | 021-34661275 15301693058 | yajikit@163.com | China | 9925 | 58 |
| Shanghai Huzhen Industrial Co., LTD | 021-60345367 13916550749 | sales@shzbio.com | China | 9965 | 58 |
| Shanghai Yubo Biotechnology Co., Ltd | 021-60514606 18321282235 | sale1@shybsw.net | China | 8165 | 58 |
| shlmai | 021-67680335 13052188602 | sale1@shlmai.net | China | 10000 | 58 |
| Supplier | Advantage |
|---|---|
| Shanghai Yaji Biological Technology Co., Ltd. | 58 |
| Shanghai Huzhen Industrial Co., LTD | 58 |
| Shanghai Yubo Biotechnology Co., Ltd | 58 |
| shlmai | 58 |
